Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Denali Therapeutics ( (DNLI) ) just unveiled an update.
Denali Therapeutics Inc. secured $200 million in gross proceeds on March 27, 2026, upon closing a synthetic royalty funding agreement with Royalty Pharma. The transaction closed shortly after the U.S. Food and Drug Administration granted accelerated approval to Denali’s drug tividenofusp alfa on March 24, 2026, providing the company with significant non-dilutive capital to support its operations and reinforcing its position in the neurodegenerative disease therapeutics market.
The most recent analyst rating on (DNLI) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Denali Therapeutics stock, see the DNLI Stock Forecast page.
Spark’s Take on DNLI Stock
According to Spark, TipRanks’ AI Analyst, DNLI is a Neutral.
The score is held back primarily by weak financial performance (widening losses, ongoing cash burn, and recent zero reported revenue), partially offset by a strong corporate catalyst (FDA accelerated approval for AVLAYAH). Technicals are modestly constructive but mixed, while valuation remains challenged due to loss-making status and no dividend support.
To see Spark’s full report on DNLI stock, click here.
More about Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative and other serious neurological diseases. Its portfolio includes biological drug candidates such as tividenofusp alfa, targeting conditions with high unmet medical need in the U.S. and global markets.
Average Trading Volume: 1,794,666
Technical Sentiment Signal: Sell
Current Market Cap: $2.87B
Find detailed analytics on DNLI stock on TipRanks’ Stock Analysis page.